The interface recombination velocity was measured by means of the photoacoustic (PA) technique in a heat transmission configuration, in which minority carriers are photoexcited
at the CdTe layer after illumination through the substrate and the CdS thin film. For data processing, a theoretical model was developed for check details the generation of the PA signal. We show a reduction in the value of the recombination velocity respecting those obtained for samples where CdS was grown by CSVT, and we observe that a minimal value appears for a thiourea/CdCl2 ratio in the CdS deposition solution equal to 5. These results show a good correlation with those of electrical buy JQEZ5 measurements performed in solar cell devices. (C) 2010 American Institute of Physics. [doi:10.1063/1.3431534]“
“Background:
Young infants are susceptible to developmental factors influencing the pharmacokinetics of drugs. Fluconazole is increasingly used to prevent and treat invasive candidiasis in infants. Dosing guidance remains empiric and variable because limited pharmacokinetic data exist.
Methods: Our population pharmacokinetic model derived from 357 fluconazole plasma concentrations from 55 infants (23-40 week gestation) illustrates expected changes in fluconazole clearance based upon gestational age, postnatal age, weight, and creatinine. We used a Monte Carlo simulation approach based on parametric description of a patient population’s pharmacokinetic response to fluconazole
to predict fluconazole exposure (median: 10th and 90th percentile population variability range) after 3, 6, and 12 mg/kg dosing.
Results: For the treatment of invasive candidiasis, a dose of in least 12 mg/kg/d in the first 90 days after birth is needed to achieve an area under the concentration curve (AUC) of >400 mg*h/L and all AUC/minimum inhibitory concentration (MIC) >50 for Candida species with MIC <8 mu g/mL in >= 90%o of <30 week gestation infants and 80% S3I-201 manufacturer of 30 to 40 week gestation infants. The more preterm infants achieve a higher median AUC (682 mg*hr/L) compared with more mature infants (520 mg*hr/L). For early Prevention of candidiasis in 23 to 29 week infants, a dose of 3 or 6 mg/kg twice weekly during the first 42 days of life is equivalent to all AUC of 50 and 100 mg*hr/L, respectively, and maintains fluconazole concentrations >= 2 or 4 mu g/mL, respectively, for half of the dosing interval. For late prevention, the 6 mg/kg dose every 72 hours provides similar exposure to 3 mg/kg daily dose. Infants with scrum creatinine >= 1.3 mg/dL have delayed drug clearance and dose adjustment is indicated if creatinine does not improve within 96 hours.